Latest Breaking News On - மேரி ரெட்மேன் - Page 1 : comparemela.com

email article Patients with advanced non-small cell lung cancer (NSCLC) and PD-L1 scores 1%-49% who received chemoimmunotherapy regimens seemed to do better than patients treated with immunotherapy alone, according to an exploratory pooled analysis. Median overall survival (OS) among patients treated with FDA-approved immunotherapy agents was 14.5 months versus a median OS of 21.4 months for patients given chemoimmunotherapy (HR 0.68, 95% CI 0.52-0.90). Median progression-free survival (PFS) was 4.2 months versus 7.78, respectively (HR 0.68, 95% CI 0.52-0.90), reported Oladimeji Akinboro, MD, of the FDA Center for Drug Evaluation and Research in Silver Spring, Maryland, at the American Society of Clinical Oncology virtual meeting. Akinboro acknowledged that the results were limited by the study designed, which compared results across clinical trials an often-used method that is statistically challenged. These results are hypothesis generating, he stressed, nothing that

United statesSilver springFort pierceEd susmanOladimeji akinboroMary redmanAmerican society of clinical oncologyResearch in silver springFred hutchinson cancer research centerDrug evaluationAmerican societyClinical oncologyஒன்றுபட்டது மாநிலங்களில்வெள்ளி வசந்தகோட்டை துளைஎட் சுஸ்மான்